Latest From Exscientia Ltd.
Vant deal, discovery platforms help Japanese firm build out pipeline before it faces the first expiries for its top seller.
The hype around Artificial Intelligence has been deafening in recent years, but real progress can only come when drug discovery culture and regulators catch up with the technology.
New five-year deal shows convergence of big pharma and big tech continues – though both sectors are wary of hype surrounding AI and digital health.
Sanofi says the virtual innovation lab it will create with Google will enable precision health care and optimize R&D and commercial operations. Incoming CEO Hudson has been tasked with improving the pharma’s R&D and digital capabilities.
- Drug Discovery Tools
- Digital Health
- Therapeutic Areas
- Metabolic Disorders
- Neurology, Nervous System
- Western Europe
- Parent & Subsidiaries
- Exscientia Ltd.
- Senior Management
Andrew Hopkins, CEO
Georgy Egorov, CFO
Mark Swindells, PhD, COO
Jeremy Besnard, PhD, Chief Designer
Richard Bickerton, PhD, CIO
Andy Bell, PhD, Chief Research officer
Richard Cox, MSc, Dir, Engineering
Adrian Schreyer, PhD, CTO
Heather Togwell, Ops Manager
- Contact Info
Dundee Incubator, James Lindsay Place
Dundee, DD1 5JJ
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.